Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Vandetanib (Primary)
- Indications Carcinoma; Liver metastases; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Apr 2020 Planned End Date changed from 27 Jul 2022 to 31 May 2020.
- 18 Apr 2020 Planned primary completion date changed from 1 Apr 2022 to 31 May 2020.